Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesThe use of omalizumab in the treatment of severe allergic asthma: A clinical experience update
Respiratory Medicine, 06/30/09
Holgate S et al. - Based on clinical trial data analysis, it is recommended that treatment response is evaluated by the physician after 16 weeks of therapy. Treatment should only be continued in responders, i.e. those judged by the physician to have achieved a marked improvement or complete asthma control. Omalizumab is generally well tolerated. Anaphylactic-like reactions are rare and less common than encountered with other biologics.
Related Articles
Reduced FcεRI-Mediated Release of Asthma-Promoting Cytokines and Chemokines from Human Basophils during Omalizumab Therapy
International Archives of Allergy and Immunology, 10/21/09
Relevance Score: 87%
Relationship between pretreatment specific IgE and the response to omalizumab therapy
Allergy, 11/12/09
Relevance Score: 85%
Effects of omalizumab on markers of inflammation in patients with allergic asthma
Allergy, 11/16/09
Relevance Score: 84%
“Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study
Respiratory Medicine, 10/13/09
Relevance Score: 84%
Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma
Allergy and Asthma Proceedings, 10/12/09
Relevance Score: 83%
Today in Asthma/Atopy...keeping you current
Receive free subspecialty "5-minute updates" via email
Parental occupation is a risk factor for childhood wheeze and asthma
European Respiratory Journal , 12/04/09
Pulmonary Rehabilitation and Palliative Care
Seminars in Respiratory and Critical Care Medicine, 12/04/09
Adherence Feedback to Improve Asthma Outcomes Among Inner-City Children
Pediatrics, 12/03/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer
Journal of Clinical Oncology, 12/04/09
Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD: a systematic review and meta-analysis
European Respiratory Journal , 12/03/09
Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis
Journal of Cystic Fibrosis , 12/02/09
Sponsor
Article Search
Sponsor